ES2157601T3 - Uso de agentes anti-microtubulos para tratar o prevenir la esclerosis multiple. - Google Patents
Uso de agentes anti-microtubulos para tratar o prevenir la esclerosis multiple.Info
- Publication number
- ES2157601T3 ES2157601T3 ES97945697T ES97945697T ES2157601T3 ES 2157601 T3 ES2157601 T3 ES 2157601T3 ES 97945697 T ES97945697 T ES 97945697T ES 97945697 T ES97945697 T ES 97945697T ES 2157601 T3 ES2157601 T3 ES 2157601T3
- Authority
- ES
- Spain
- Prior art keywords
- multiple sclerosis
- treat
- prevent multiple
- microtuble
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
- A61L31/10—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/606—Coatings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- Surgery (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Biophysics (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
Abstract
LA INVENCION SUMINISTRA PROCEDIMIENTOS PARA EL TRATAMIENTO O LA PREVENCION DE ENFERMEDADES INFLAMATORIAS TALES COMO LA PSORIASIS O LA ESCLEROSIS MULTIPLE, QUE COMPRENDE EL PASO DE ADMINISTRAR EN LA ZONA DE LA INFLAMACION UN AGENTE ANTIMICROTUBITO, O UN ANALOGO O UN DERIVADO DEL MISMO.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3221596P | 1996-12-02 | 1996-12-02 | |
US6308797P | 1997-10-24 | 1997-10-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2157601T3 true ES2157601T3 (es) | 2001-08-16 |
Family
ID=26708132
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES97945697T Expired - Lifetime ES2157601T3 (es) | 1996-12-02 | 1997-12-02 | Uso de agentes anti-microtubulos para tratar o prevenir la esclerosis multiple. |
ES00123534T Expired - Lifetime ES2207451T3 (es) | 1996-12-02 | 1997-12-02 | Uso de agentes anti-microtubulos para tratar enfermedades inflamatorias respiratorias del tracto respiratorio. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES00123534T Expired - Lifetime ES2207451T3 (es) | 1996-12-02 | 1997-12-02 | Uso de agentes anti-microtubulos para tratar enfermedades inflamatorias respiratorias del tracto respiratorio. |
Country Status (21)
Country | Link |
---|---|
US (1) | US6515016B2 (es) |
EP (5) | EP1070502B1 (es) |
JP (3) | JP3287852B2 (es) |
KR (2) | KR100809304B1 (es) |
CN (4) | CN101011576B (es) |
AR (1) | AR013878A1 (es) |
AT (4) | ATE457170T1 (es) |
AU (1) | AU735655B2 (es) |
BR (1) | BR9713673A (es) |
CA (2) | CA2273240C (es) |
DE (4) | DE69739761D1 (es) |
DK (1) | DK0941089T3 (es) |
ES (2) | ES2157601T3 (es) |
GR (1) | GR3036364T3 (es) |
HK (3) | HK1022270A1 (es) |
NO (2) | NO322610B1 (es) |
NZ (5) | NZ538260A (es) |
PT (1) | PT941089E (es) |
RU (2) | RU2242974C2 (es) |
TW (1) | TW562674B (es) |
WO (1) | WO1998024427A2 (es) |
Families Citing this family (177)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
US7611533B2 (en) * | 1995-06-07 | 2009-11-03 | Cook Incorporated | Coated implantable medical device |
CA2178541C (en) * | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
JP4183099B2 (ja) | 1995-11-17 | 2008-11-19 | ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング(ゲー・ベー・エフ) | エポチロンcおよびd、製造法ならびに組成物 |
CN100344627C (zh) | 1996-11-18 | 2007-10-24 | 生物技术研究有限公司(Gbf) | 埃坡霉素c、其制备方法以及作为细胞抑制剂和植物保护剂的应用 |
US20030157187A1 (en) * | 1996-12-02 | 2003-08-21 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating or preventing inflammatory diseases |
US6495579B1 (en) | 1996-12-02 | 2002-12-17 | Angiotech Pharmaceuticals, Inc. | Method for treating multiple sclerosis |
US6605599B1 (en) | 1997-07-08 | 2003-08-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
US6365749B1 (en) | 1997-12-04 | 2002-04-02 | Bristol-Myers Squibb Company | Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs |
US6320045B1 (en) | 1997-12-04 | 2001-11-20 | Bristol-Myers Squibb Company | Process for the reduction of oxiranyl epothilones to olefinic epothilones |
FR2775187B1 (fr) | 1998-02-25 | 2003-02-21 | Novartis Ag | Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo |
US6498257B1 (en) | 1998-04-21 | 2002-12-24 | Bristol-Myers Squibb Company | 2,3-olefinic epothilone derivatives |
US6399638B1 (en) | 1998-04-21 | 2002-06-04 | Bristol-Myers Squibb Company | 12,13-modified epothilone derivatives |
US6632457B1 (en) * | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
US6264991B1 (en) * | 1998-08-18 | 2001-07-24 | Southern Research Institute | Compositions and methods for treating intracellular infections |
AU5925399A (en) * | 1998-09-16 | 2000-04-03 | Oncopharmaceutical, Inc. | Treatment of oncologic tumors with an injectable formulation of a golgi apparatus disturbing agent |
US6127406A (en) * | 1998-10-09 | 2000-10-03 | Harbor Branch Oceanographic Institution, Inc. | Discodermolide compounds and methods of use |
US6494879B2 (en) | 1998-10-15 | 2002-12-17 | Scimed Life Systems, Inc. | Treating urinary retention |
US6780620B1 (en) | 1998-12-23 | 2004-08-24 | Bristol-Myers Squibb Company | Microbial transformation method for the preparation of an epothilone |
US7485317B1 (en) | 1999-02-05 | 2009-02-03 | The Regents Of The University Of California | Thermo-reversible polymer for intralumenal implant |
NZ513629A (en) | 1999-02-22 | 2004-01-30 | Bristol Myers Squibb Co | C-21 modified epothilones |
US6291684B1 (en) | 1999-03-29 | 2001-09-18 | Bristol-Myers Squibb Company | Process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
ATE244558T1 (de) | 1999-04-16 | 2003-07-15 | Novo Nordisk As | Trockene formbare arzneistoffformulierung |
DE60042853D1 (de) * | 1999-04-26 | 2009-10-08 | Glaukos Corp | Shunteinrichtung zur Glaukombehandlung |
US20040015079A1 (en) * | 1999-06-22 | 2004-01-22 | Teratech Corporation | Ultrasound probe with integrated electronics |
GB9918429D0 (en) * | 1999-08-04 | 1999-10-06 | Novartis Ag | Organic compounds |
AU781986B2 (en) | 1999-11-05 | 2005-06-23 | Cytovia, Inc. | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
US8883856B2 (en) | 2000-02-28 | 2014-11-11 | John Jackson | Compositions and methods for the treatment of inflammatory diseases using topoisomerase inhibitors |
AU2001247241A1 (en) | 2000-03-01 | 2001-09-12 | Harbor Branch Oceanographic Institution, Inc. | Biologically active analogs of discodermolide |
US6518421B1 (en) | 2000-03-20 | 2003-02-11 | Bristol-Myers Squibb Company | Process for the preparation of epothilone analogs |
US6593115B2 (en) | 2000-03-24 | 2003-07-15 | Bristol-Myers Squibb Co. | Preparation of epothilone intermediates |
DE10015479A1 (de) * | 2000-03-29 | 2001-10-11 | Basf Ag | Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität |
US8101200B2 (en) * | 2000-04-13 | 2012-01-24 | Angiotech Biocoatings, Inc. | Targeted therapeutic agent release devices and methods of making and using the same |
US6489314B1 (en) * | 2001-04-03 | 2002-12-03 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
US20050095268A1 (en) * | 2000-06-12 | 2005-05-05 | Acorn Cardiovascular, Inc. | Cardiac wall tension relief with cell loss management |
WO2001098286A1 (en) | 2000-06-22 | 2001-12-27 | Nitromed, Inc. | Nitrosated and nitrosylated taxanes, compositions and methods of use |
UA75365C2 (en) | 2000-08-16 | 2006-04-17 | Bristol Myers Squibb Co | Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon |
PT1411954E (pt) | 2000-10-18 | 2011-03-16 | Pharmasset Inc | Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal |
JP2002154963A (ja) * | 2000-11-14 | 2002-05-28 | Yakult Honsha Co Ltd | 徐放性抗腫瘍剤 |
HU229349B1 (en) | 2001-01-25 | 2013-11-28 | Bristol Myers Squibb Co | Methods for preparation of pharmaceutical composition containing epothilone analogs useful for treatment of cancer |
WO2002058699A1 (en) | 2001-01-25 | 2002-08-01 | Bristol-Myers Squibb Company | Pharmaceutical forms of epothilones for oral administration |
EP1353667A1 (en) | 2001-01-25 | 2003-10-22 | Bristol-Myers Squibb Company | Parenteral formulations containing epothilone analogs |
US6893859B2 (en) | 2001-02-13 | 2005-05-17 | Kosan Biosciences, Inc. | Epothilone derivatives and methods for making and using the same |
CN1774253A (zh) | 2001-02-20 | 2006-05-17 | 布里斯托尔-迈尔斯斯奎布公司 | 用环氧丙酯酮衍生物治疗顽固性肿瘤 |
EE200300397A (et) | 2001-02-20 | 2003-12-15 | Bristol-Myers Squibb Company | Epotilooni derivaadid refraktaarsete kasvajate raviks |
EP1418945A2 (en) * | 2001-03-13 | 2004-05-19 | Angiotech Pharmaceuticals, Inc. | Micellar drug delivery vehicles and uses thereof |
US7312237B2 (en) | 2001-03-14 | 2007-12-25 | Bristol-Myers Squibb Co. | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
US7771468B2 (en) * | 2001-03-16 | 2010-08-10 | Angiotech Biocoatings Corp. | Medicated stent having multi-layer polymer coating |
DE10115740A1 (de) * | 2001-03-26 | 2002-10-02 | Ulrich Speck | Zubereitung für die Restenoseprophylaxe |
EP1800670A1 (en) * | 2001-04-20 | 2007-06-27 | The University of British Columbia | Micellar drug delivery systems for hydrophobic drugs |
WO2002087563A2 (en) * | 2001-05-01 | 2002-11-07 | Angiotech Pharmaceuticals Inc. | Compositions comprising an anti-microtubule agent and a polypeptide or a polysaccharide and the use thereof for the preparation of a medicament for the treatment of inflammatory conditions |
US20030157161A1 (en) * | 2001-05-01 | 2003-08-21 | Angiotech Pharmaceuticals, Inc. | Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents |
JP4593880B2 (ja) | 2001-05-16 | 2010-12-08 | サイトビア インコーポレイテッド | カスパーゼの活性化因子およびアポトーシスの誘導因子としての置換された4h−クロメンおよび類似体、並びにその使用方法 |
US6858607B1 (en) | 2001-05-16 | 2005-02-22 | Cytovia, Inc. | 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
WO2002098868A1 (en) | 2001-06-01 | 2002-12-12 | Bristol-Myers Squibb Company | Epothilone derivatives |
IL145751A (en) * | 2001-10-04 | 2010-12-30 | Avi Dascalu | Use of aluminum fluoride for the preparation of compositions for the treatment of acne vulgaris and folliculitis |
US7582670B2 (en) * | 2001-12-13 | 2009-09-01 | Natrogen Therapeutics, Inc. | Methods of treating an inflammatory-related disease |
US8454997B2 (en) | 2001-12-18 | 2013-06-04 | Novo Nordisk A/S | Solid dose micro implant |
BR0215184A (pt) * | 2001-12-20 | 2006-06-06 | Bristol Myers Squibb Co | composições farmacêuticas de derivados de taxano oralmente ativos tendo biodisponibilidade aumentada |
US20030194421A1 (en) * | 2001-12-28 | 2003-10-16 | Angiotech Pharmaceuticals, Inc. | Treatment of uveitis |
EP1340498A1 (en) * | 2002-03-01 | 2003-09-03 | Schering Aktiengesellschaft | Use of epothilones in the treatment of brain diseases associated with proliferative processes |
EP1507773B1 (en) | 2002-03-08 | 2015-09-16 | Eisai R&D Management Co., Ltd. | Macrocyclic compounds useful as pharmaceuticals |
AU2003218107A1 (en) | 2002-03-12 | 2003-09-29 | Bristol-Myers Squibb Company | C12-cyano epothilone derivatives |
ES2337134T3 (es) | 2002-03-12 | 2010-04-21 | Bristol-Myers Squibb Company | Derivados de c3-ciano-epotilona. |
MXPA04009209A (es) | 2002-03-22 | 2004-11-26 | Eisai Co Ltd | Derivados de hemiasterlina y usos de los mismos. |
TW200403994A (en) | 2002-04-04 | 2004-03-16 | Bristol Myers Squibb Co | Oral administration of EPOTHILONES |
TW200400191A (en) | 2002-05-15 | 2004-01-01 | Bristol Myers Squibb Co | Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
AU2003230411A1 (en) | 2002-05-16 | 2003-12-02 | Cytovia, Inc. | Substituted 4-aryl-4h-pyrrolo(2,3-h)chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
US7476741B2 (en) | 2002-05-16 | 2009-01-13 | Cytovia, Inc. | Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof |
AU2003243561A1 (en) | 2002-06-14 | 2003-12-31 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
WO2004006976A1 (en) * | 2002-07-12 | 2004-01-22 | Cook Incorporated | Coated medical device |
DE10244847A1 (de) | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medizinische Vorrichtung zur Arzneimittelabgabe |
EP1542998A4 (en) | 2002-09-23 | 2007-01-31 | Bristol Myers Squibb Co | PROCESS FOR THE PREPARATION, ISOLATION AND PURIFICATION OF EPOTHILON B, AND RINSE CRYSTAL STRUCTURES OF EPOTHILON B |
BR0314743A (pt) * | 2002-09-26 | 2005-07-26 | Angiotech Int Ag | Envoltórios perivasculares |
WO2004038752A2 (en) * | 2002-10-21 | 2004-05-06 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Contiguous capillary electrospray sources and analytical device |
JP2006515291A (ja) * | 2002-12-09 | 2006-05-25 | ノバルティス アクチエンゲゼルシャフト | ステントに入れて狭窄症を処置するための微小管安定化剤 |
EP1605863B1 (en) | 2003-03-14 | 2016-09-07 | Intersect ENT, Inc. | Sinus delivery of sustained release therapeutics |
US6989370B2 (en) * | 2003-05-01 | 2006-01-24 | The United States Of America As Represented By The Secretary Of Agriculture | Bacteriocins and novel bacterial strains |
US7229979B2 (en) * | 2003-06-23 | 2007-06-12 | Immune Modulation, Inc. | Hypoestoxides, derivatives and agonists thereof for use as stent-coating agents |
WO2005007129A2 (en) * | 2003-07-17 | 2005-01-27 | Angiotech International Ag | Topical formulations with bioactive components |
US20050095283A1 (en) * | 2003-09-16 | 2005-05-05 | Aphios Corporation | Compositions and methods for topically treating diseases |
EP1682196A2 (en) * | 2003-11-10 | 2006-07-26 | Angiotech International Ag | Medical implants and anti-scarring agents |
US20050208095A1 (en) * | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
JP2007514472A (ja) * | 2003-11-20 | 2007-06-07 | アンジオテック インターナショナル アーゲー | 軟組織移植片および瘢痕化抑制剤 |
WO2005068020A1 (en) | 2004-01-02 | 2005-07-28 | Advanced Cardiovascular Systems, Inc. | High-density lipoprotein coated medical devices |
US20050186261A1 (en) * | 2004-01-30 | 2005-08-25 | Angiotech International Ag | Compositions and methods for treating contracture |
EP1559447A1 (en) * | 2004-01-30 | 2005-08-03 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism |
US20060211752A1 (en) | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
WO2005089800A1 (ja) * | 2004-03-17 | 2005-09-29 | Locomogene, Inc. | hsHRD3を含む医薬組成物 |
US7989490B2 (en) | 2004-06-02 | 2011-08-02 | Cordis Corporation | Injectable formulations of taxanes for cad treatment |
US8003122B2 (en) * | 2004-03-31 | 2011-08-23 | Cordis Corporation | Device for local and/or regional delivery employing liquid formulations of therapeutic agents |
US20050266043A1 (en) * | 2004-05-27 | 2005-12-01 | Medtronic Vascular, Inc. | Methods and compounds for treatment of aneurysmal tissue |
WO2006002365A2 (en) * | 2004-06-24 | 2006-01-05 | Angiotech International Ag | Microparticles with high loadings of a bioactive agent |
US20060142198A1 (en) * | 2004-07-02 | 2006-06-29 | Wound Care Partners Llc | Compositions for treating wounds and processes for their preparation |
US8119153B2 (en) * | 2004-08-26 | 2012-02-21 | Boston Scientific Scimed, Inc. | Stents with drug eluting coatings |
US20100093767A1 (en) * | 2004-12-03 | 2010-04-15 | Takeda San Diego, Inc. | Mitotic Kinase Inhibitors |
USH2260H1 (en) | 2005-02-17 | 2011-07-05 | Angiotech International Ag | Stents combined with paclitaxel derivatives |
EP1700596A1 (en) * | 2005-03-09 | 2006-09-13 | Max-Planck-Gesellschaft Zur Förderung Der Wissenschaften E.V. | Use of microtubule stabilizing compounds for the treatment of lesions of CNS axons |
US20060222627A1 (en) * | 2005-03-30 | 2006-10-05 | Andrew Carter | Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue |
AU2006231506B2 (en) | 2005-04-04 | 2012-08-30 | Intersect Ent, Inc. | Device and methods for treating paranasal sinus conditions |
US20060224095A1 (en) * | 2005-04-05 | 2006-10-05 | University Of New Hampshire | Biocompatible polymeric vesicles self assembled from triblock copolymers |
US8002738B2 (en) * | 2005-05-17 | 2011-08-23 | Boston Scientific Scimed, Inc. | Self-adhering lesion formation apparatus and methods |
JP5846711B2 (ja) * | 2005-06-09 | 2016-01-20 | メダ アーベー | 炎症性疾患の治療のための方法及び組成物 |
ITMI20051826A1 (it) * | 2005-09-29 | 2007-03-30 | Novachem S A | Kit per la somministrazione parenterale di medicamenti |
US20070196423A1 (en) * | 2005-11-21 | 2007-08-23 | Med Institute, Inc. | Implantable medical device coatings with biodegradable elastomer and releasable therapeutic agent |
BRPI0708446A2 (pt) * | 2006-03-01 | 2011-06-07 | Janssen Pharmaceutica Nv | tratamento de cáncer combinando agente de linfodepleção com ctls e citocinas |
US20070275035A1 (en) * | 2006-05-24 | 2007-11-29 | Microchips, Inc. | Minimally Invasive Medical Implant Devices for Controlled Drug Delivery |
US9173773B2 (en) * | 2006-06-21 | 2015-11-03 | Johnson & Johnson Vision Care, Inc. | Punctal plugs for the delivery of active agents |
US8066824B2 (en) * | 2006-07-07 | 2011-11-29 | Intezyne Technologies, Inc. | Covalent modification of metal surfaces |
US20100150844A1 (en) * | 2006-07-28 | 2010-06-17 | The Johns Hopkins University | Use of 8-quinolinol and its analogs to target cancer stem cells |
US20080085293A1 (en) * | 2006-08-22 | 2008-04-10 | Jenchen Yang | Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor |
US20080051702A1 (en) * | 2006-08-24 | 2008-02-28 | Herrmann Robert A | Therapeutic agent delivery for the treatment of asthma via implantable and insertable medical devices |
DE102006049185A1 (de) * | 2006-10-18 | 2008-04-24 | Bayerl, Thomas M., Prof. Dr. | Verwendung von Deuteriumdioxid zur Behandlung von hyperproliferativen Erkrankungen der Haut |
US9474833B2 (en) * | 2006-12-18 | 2016-10-25 | Cook Medical Technologies Llc | Stent graft with releasable therapeutic agent and soluble coating |
EP1964560A1 (en) * | 2007-02-28 | 2008-09-03 | Helmholtz-Zentrum für Infektionsforschung GmbH | Use of inhibitors of the degradation of p27 for the treatment of cancer |
ES2310122B1 (es) * | 2007-04-20 | 2009-10-30 | Instituto Cientifico Y Tecnologico De Navarra, S.A | Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones. |
ITMI20071267A1 (it) * | 2007-06-22 | 2008-12-23 | Fidia Farmaceutici | Uso di coniugati dell'acido ialuronico nel trattamento locale di malattie cutanee iperproliferative |
DE102007031397A1 (de) | 2007-07-05 | 2009-01-08 | D2O Bioscience Group Ltd. | Verwendung von Deuteriumoxid zur Behandlung von Virus-basierten Erkrankungen der Haut |
UA97988C2 (en) * | 2007-07-26 | 2012-04-10 | АКТИС АйПи БВ | Microparticles comprising pcl and uses thereof |
EP2050814A1 (en) * | 2007-10-17 | 2009-04-22 | Txcell | Compositions for treating multiple sclerosis |
CN101945621B (zh) | 2007-12-18 | 2014-06-18 | 因特尔赛克特耳鼻喉公司 | 自扩展装置及用于其的方法 |
US8420110B2 (en) * | 2008-03-31 | 2013-04-16 | Cordis Corporation | Drug coated expandable devices |
US8409601B2 (en) * | 2008-03-31 | 2013-04-02 | Cordis Corporation | Rapamycin coated expandable devices |
KR101100867B1 (ko) * | 2008-05-14 | 2012-01-02 | 주식회사 운화 | 주목의 형성층 또는 전형성층 유래 식물줄기세포주를 유효성분으로 함유하는 항산화, 항염증 또는 항노화용 조성물 |
US8642063B2 (en) * | 2008-08-22 | 2014-02-04 | Cook Medical Technologies Llc | Implantable medical device coatings with biodegradable elastomer and releasable taxane agent |
PL2331075T3 (pl) * | 2008-08-29 | 2016-04-29 | Genzyme Corp | Formulacje peptydowe o kontrolowanym uwalnianiu |
DE102009003992A1 (de) * | 2009-01-07 | 2010-07-08 | D2O Biosience Group Ltd., Hamilton | Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Respirationstraktes |
DE102009003942A1 (de) | 2009-01-07 | 2010-07-08 | D2O Biosience Group Ltd., Hamilton | Verwendung von Deuteriumoxid zur Behandlung Virus-basierter Erkrankungen des Auges |
PL2387390T3 (pl) * | 2009-01-13 | 2013-12-31 | Pergamum Ab | Zawierające kwas hialuronowy kompozycje do leczenia ran, blizn oraz zrostów powstających po zabiegach chirurgicznych |
DE102009011931A1 (de) | 2009-03-10 | 2010-09-16 | Innora Gmbh | Vorrichtung zur Applikation von Wirkstoffen auf die Wand eines Körpergefäßes |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US20110021869A1 (en) * | 2009-07-24 | 2011-01-27 | Hilary John Cholhan | Single-incision minimally-invasive surgical repair of pelvic organ/vaginal prolapse conditions |
GB0917817D0 (en) | 2009-10-12 | 2009-11-25 | Biotica Tech Ltd | Novel compounds and methods for their production |
GB0917816D0 (en) | 2009-10-12 | 2009-11-25 | Biotica Tech Ltd | Novel compounds and methods for their production |
CA3037168A1 (en) | 2009-12-18 | 2011-06-23 | Interface Biologics, Inc. | Local delivery of drugs from self assembled coatings |
US8945156B2 (en) | 2010-05-19 | 2015-02-03 | University Of Utah Research Foundation | Tissue fixation |
US8858577B2 (en) | 2010-05-19 | 2014-10-14 | University Of Utah Research Foundation | Tissue stabilization system |
US8852214B2 (en) | 2011-02-04 | 2014-10-07 | University Of Utah Research Foundation | System for tissue fixation to bone |
RU2451680C1 (ru) | 2011-02-21 | 2012-05-27 | Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" | Клатратный комплекс циклодекстрина или арабиногалактана с 9-фенил-симм-октагидроселеноксантеном, способ его получения (варианты), фармацевтическая композиция и лекарственное средство |
US20120315303A1 (en) * | 2011-05-05 | 2012-12-13 | Medtronic Vascular, Inc. | Methods and intravascular treatment devices using paclitaxel for treatment of atherosclerosis |
WO2013057062A1 (en) * | 2011-10-18 | 2013-04-25 | Nestec S.A. | Composition for use in the promotion of intestinal angiogenesis and of nutrient absorption and of enteral feeding tolerance and/or in the prevention and/or treatment of intestinal inflammation and/or in the recovery after intestinal injury and surgery |
US9220759B2 (en) | 2012-02-23 | 2015-12-29 | Abbott Cardiovascular Systems Inc. | Treatment of diabetic patients with a drug eluting stent and adjunctive therapy |
US9220584B2 (en) | 2012-03-30 | 2015-12-29 | Abbott Cardiovascular Systems Inc. | Treatment of diabetic patients with a stent and locally administered adjunctive therapy |
US11253252B2 (en) | 2012-07-30 | 2022-02-22 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
US10219804B2 (en) | 2012-07-30 | 2019-03-05 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
US11957334B2 (en) | 2012-07-30 | 2024-04-16 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
US9427309B2 (en) | 2012-07-30 | 2016-08-30 | Conextions, Inc. | Soft tissue repair devices, systems, and methods |
US10390935B2 (en) | 2012-07-30 | 2019-08-27 | Conextions, Inc. | Soft tissue to bone repair devices, systems, and methods |
US10835241B2 (en) | 2012-07-30 | 2020-11-17 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
US11944531B2 (en) | 2012-07-30 | 2024-04-02 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
RU2715103C2 (ru) * | 2013-05-03 | 2020-02-27 | Липидор Аб | Местная композиция и носитель для введения фармацевтически или косметически активных ингредиентов |
RU2525181C1 (ru) * | 2013-07-26 | 2014-08-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИ КПССЗ" СО РАМН) | Способ изготовления биодеградируемых мембран для предотвращения образования спаек после кардиохирургических операций |
US11583384B2 (en) | 2014-03-12 | 2023-02-21 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
WO2015138760A1 (en) | 2014-03-12 | 2015-09-17 | Conextions, Inc. | Soft tissue repair devices, systems, and methods |
KR102348707B1 (ko) * | 2014-08-12 | 2022-01-06 | 주식회사 엘지생활건강 | 도세탁셀 또는 이의 약학적으로 허용가능한 염을 포함하는 피부 탄력, 주름개선, 보습 또는 항염증용 화장료 또는 약학 조성물 |
KR102263764B1 (ko) * | 2014-08-13 | 2021-06-09 | 주식회사 엘지생활건강 | 세팔로만닌 또는 이의 약학적으로 허용가능한 염을 포함하는 피부 미백 또는 항염증용 화장료 또는 약학 조성물 |
CN104546931B (zh) * | 2014-09-30 | 2019-04-09 | 深圳华大基因科技有限公司 | 华德萨特氏菌在治疗或预防类风湿性关节炎或其相关疾病中的应用 |
WO2016176333A1 (en) | 2015-04-27 | 2016-11-03 | Reflex Medical, Inc. | Systems and mehtods for sympathetic cardiopulmonary neuromodulation |
KR20180030416A (ko) * | 2015-08-05 | 2018-03-22 | 칠드런'즈 메디컬 센터 코포레이션 | 약물 전달을 위한 침투 증강제를 수반한 조성물 |
RU2018113280A (ru) | 2015-09-16 | 2019-10-16 | ДиЭфБи СОРИА, ЭлЭлСи | Доставка наночастиц лекарственного средства и способы их использования |
US11246879B2 (en) | 2016-02-09 | 2022-02-15 | Tulai Therapeutics, Inc. | Methods, agents, and devices for local neuromodulation of autonomic nerves |
KR20180000682A (ko) * | 2016-06-22 | 2018-01-03 | 서울대학교산학협력단 | 5-(3',4'-디히드록시페닐)-감마-발레로락톤을 함유하는 동맥경화 개선용 식품 조성물 및 동맥경화 예방 및 치료용 약학 조성물 |
EP3478287A4 (en) | 2016-06-29 | 2020-04-08 | Tulavi Therapeutics, Inc. | TREATMENT OF SEPTICEMIA AND ASSOCIATED INFLAMMATORY CONDITIONS BY LOCAL NEUROMODULATION OF THE AUTONOMOUS NERVOUS SYSTEM |
US11696822B2 (en) | 2016-09-28 | 2023-07-11 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
WO2018170196A1 (en) | 2017-03-15 | 2018-09-20 | Dfb Soria, Llc | Topical therapy for the treatment of skin malignancies using nanoparticles of taxanes |
KR20200003827A (ko) | 2017-04-14 | 2020-01-10 | 젤레시스 엘엘씨 | 장 투과성-관련 장애를 치료 또는 예방하기 위한 조성물 및 방법 |
CN106943380B (zh) * | 2017-05-17 | 2021-02-05 | 杜楠 | Vegf单抗联合纳米紫杉醇在制备治疗癌性腹腔粘连药物中的应用 |
US11547397B2 (en) | 2017-12-20 | 2023-01-10 | Conextions, Inc. | Devices, systems, and methods for repairing soft tissue and attaching soft tissue to bone |
JP2021514288A (ja) | 2018-02-20 | 2021-06-10 | コネクションズ, インク.Conextions, Inc. | 軟質組織を修復し、軟質組織を骨に取り付けるための装置、システム、および方法 |
US10974022B2 (en) * | 2018-02-28 | 2021-04-13 | Gyrus Acmi, Inc. | Nasal implant assembly |
US11497726B2 (en) | 2018-03-16 | 2022-11-15 | Dfb Soria, Ll. | Topical therapy for the treatment of cervical intraepithelial neoplasia (CIN) and cervical cancer using nanoparticles of taxanes |
EP3790856A4 (en) * | 2018-05-08 | 2022-03-02 | University of Connecticut | LONG-ACTING LOCAL AESTHETIC FORMULATION |
JP2021531061A (ja) | 2018-05-22 | 2021-11-18 | インターフェース バイオロジクス,インコーポレーテッド | 薬物を脈管壁に送達するための組成物及び方法 |
JP7365409B2 (ja) | 2018-06-28 | 2023-10-19 | エイアールエックス エルエルシー | 溶解性単位用量膜構造物を製造するための分配方法 |
EP3817786A4 (en) | 2018-07-02 | 2022-03-23 | Tulavi Therapeutics, Inc. | METHODS AND DEVICES FOR IN SITU FORMED NERVE CAP |
RU2703257C1 (ru) * | 2018-12-04 | 2019-10-16 | Закрытое акционерное общество "СКАЙ ЛТД" | Способ лечения воспалительных процессов суставов и простатита |
CN110420072B (zh) * | 2019-07-24 | 2024-01-23 | 莆田学院 | 一种应用于机能学的大鼠灌胃装置 |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4391797A (en) | 1977-01-05 | 1983-07-05 | The Children's Hospital Medical Center | Systems for the controlled release of macromolecules |
GB2074858B (en) | 1980-04-23 | 1985-03-20 | Wellcome Found | Compositions containing 3-deazaaden-osine |
US4534899A (en) | 1981-07-20 | 1985-08-13 | Lipid Specialties, Inc. | Synthetic phospholipid compounds |
JPS6163613A (ja) | 1984-09-04 | 1986-04-01 | Mitsui Toatsu Chem Inc | 顆粒状に調整された徐放性製剤 |
US4882168A (en) | 1986-09-05 | 1989-11-21 | American Cyanamid Company | Polyesters containing alkylene oxide blocks as drug delivery systems |
US4808610A (en) | 1986-10-02 | 1989-02-28 | Schering Corporation | Mometasone furoate anti-inflammatory cream composition using hexylene glycol |
US4893623A (en) | 1986-12-09 | 1990-01-16 | Advanced Surgical Intervention, Inc. | Method and apparatus for treating hypertrophy of the prostate gland |
US5092885A (en) | 1987-02-12 | 1992-03-03 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Peptides with laminin activity |
US4753965A (en) | 1987-04-09 | 1988-06-28 | Merrell Dow Pharmaceuticals, Inc. | Method of treating multiple sclerosis with chalcone derivatives |
US4904697A (en) | 1987-04-09 | 1990-02-27 | Merrell Dow Pharmaceuticals Inc. | Controlling the growth of certain tumor tissue with chalcone derivatives |
US4863968A (en) | 1987-04-09 | 1989-09-05 | Merrell Dow Pharmaceuticals Inc. | Methods of treating gout with chalcone derivatives |
NL8701337A (nl) | 1987-06-09 | 1989-01-02 | Sentron V O F | Substraat voorzien van een bloedcompatibel oppervlak, verkregen door koppeling aan het oppervlak van een fysiologisch aktieve stof met remmende invloed op de vorming van bloedstolsels en/of in staat om gevormde bloedstolsels af te breken, alsmede werkwijze ter vervaardiging van het substraat. |
ATE145337T1 (de) | 1988-05-02 | 1996-12-15 | Phanos Tech Inc | Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen |
JP2836878B2 (ja) | 1988-08-24 | 1998-12-14 | スリピアン,マービン,ジェイ | 生分解性高分子材料による管腔内封止 |
US5676978A (en) | 1989-02-14 | 1997-10-14 | Amira, Inc. | Methods of inhibiting undesirable cell growth using a combination of a cyclocreatine compound and a hyperplastic inhibitory agent |
US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
WO1991007154A1 (en) | 1989-11-13 | 1991-05-30 | President And Fellows Of Harvard College | EXTRALUMINAL REGULATION OF THE GROWTH AND REPAIR OF TUBULAR STRUCTURES ιIN VIVO |
US5192744A (en) | 1990-01-12 | 1993-03-09 | Northwestern University | Method of inhibiting angiogenesis of tumors |
ES2093699T3 (es) | 1990-01-25 | 1997-01-01 | Childrens Hosp Medical Center | Metodo y composiciones para inhibir la angiogenesis. |
CA2049973C (en) | 1990-02-28 | 2002-12-24 | Rodney G. Wolff | Intralumenal drug eluting prosthesis |
US5407683A (en) | 1990-06-01 | 1995-04-18 | Research Corporation Technologies, Inc. | Pharmaceutical solutions and emulsions containing taxol |
WO1992000747A1 (en) | 1990-07-12 | 1992-01-23 | Sterilization Technical Services, Inc. | Anti-thrombogenic and/or anti-microbial composition |
EP0470569B1 (en) | 1990-08-08 | 1995-11-22 | Takeda Chemical Industries, Ltd. | Intravascular embolizing agent containing angiogenesis inhibiting substance |
WO1992006701A1 (en) | 1990-10-18 | 1992-04-30 | Huffstutler, M., Conrad, Jr. | Preparation of concentrated fluid symphytum extracts, therapeutic forms and methods of use |
US5466455A (en) | 1990-10-18 | 1995-11-14 | Huffstutler, Jr.; Miles C. | Polyphase fluid-extraction process, resulting products and methods of use |
MX9102128A (es) | 1990-11-23 | 1992-07-08 | Rhone Poulenc Rorer Sa | Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
AU1579092A (en) | 1991-02-27 | 1992-10-06 | Nova Pharmaceutical Corporation | Anti-infective and anti-inflammatory releasing systems for medical devices |
US5620971A (en) | 1991-05-09 | 1997-04-15 | Vertex Pharmaceuticals Incorporated | Biologically active acylated amino acid derivatives |
FR2678833B1 (fr) | 1991-07-08 | 1995-04-07 | Rhone Poulenc Rorer Sa | Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes. |
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
WO1993006792A1 (en) | 1991-10-04 | 1993-04-15 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5270047A (en) | 1991-11-21 | 1993-12-14 | Kauffman Raymond F | Local delivery of dipyridamole for the treatment of proliferative diseases |
EP0643706A1 (en) | 1991-11-27 | 1995-03-22 | Zynaxis Inc. | Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles |
CA2086642C (en) | 1992-01-09 | 2004-06-15 | Randall E. Morris | Method of treating hyperproliferative vascular disease |
US5301664A (en) | 1992-03-06 | 1994-04-12 | Sievers Robert E | Methods and apparatus for drug delivery using supercritical solutions |
US5322779A (en) | 1992-04-16 | 1994-06-21 | The Research And Development Institute, Inc. At Montana State University | Taxol production by taxomyces andreanae |
CA2094858C (en) | 1992-04-28 | 2004-06-15 | Robert D. Mitchell | Method of treating hyperproliferative vascular disease |
DE4214215A1 (de) | 1992-04-30 | 1993-11-04 | Behringwerke Ag | Verwendung von inhibitoren von plasminogenaktivatoren zur behandlung von entzuendungen |
FR2693193B1 (fr) | 1992-07-03 | 1994-09-02 | Rhone Poulenc Rorer Sa | Nouveaux dérivés de la désacétyl-10 baccatine III, leur préparation et les compositions pharmaceutiques qui les contiennent. |
CA2086874E (en) | 1992-08-03 | 2000-01-04 | Renzo Mauro Canetta | Methods for administration of taxol |
ATE234088T1 (de) | 1992-09-22 | 2003-03-15 | Us Gov Health & Human Serv | Taxol zur behandlung von lymphomen und brustkrebs und zur verminderung der multi-drug resistenz gegen taxol |
US5789189A (en) | 1993-09-24 | 1998-08-04 | The Regents Of The University Of California | Inhibition of cyst formation by cytoskeletal specific drugs |
US5770609A (en) | 1993-01-28 | 1998-06-23 | Neorx Corporation | Prevention and treatment of cardiovascular pathologies |
FR2696461B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent. |
FR2698363B1 (fr) | 1992-11-23 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouveaux dérivés du taxane, leur préparation et les compositions qui les contiennent. |
US5565439A (en) | 1992-11-24 | 1996-10-15 | The Procter & Gamble Company | Methods of using lysophosphatidic acid for treating hyperproliferative conditions |
DK0674510T3 (da) | 1992-11-27 | 1999-05-10 | Napro Biotherapeutics Inc | Injicerbart præparat omfattende paclitaxel |
ES2151541T3 (es) | 1992-12-02 | 2001-01-01 | Alkermes Inc | Microesferas que contienen hormona del crecimiento de liberacion prolongada. |
US5356927A (en) | 1992-12-02 | 1994-10-18 | Thomas Jefferson University | Methods of treating plasmodium and babesia parasitic infections |
FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
AU5735094A (en) | 1992-12-02 | 1994-06-22 | Thomas Jefferson University | Methods of killing protozoal parasites |
FR2698871B1 (fr) | 1992-12-09 | 1995-02-24 | Rhone Poulenc Rorer Sa | Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
US5443458A (en) | 1992-12-22 | 1995-08-22 | Advanced Cardiovascular Systems, Inc. | Multilayered biodegradable stent and method of manufacture |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
FR2702212B1 (fr) | 1993-03-02 | 1995-04-07 | Rhone Poulenc Rorer Sa | Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
WO1994021308A1 (en) | 1993-03-18 | 1994-09-29 | Cedars-Sinai Medical Center | Drug incorporating and releasing polymeric coating for bioprosthesis |
US5475011A (en) * | 1993-03-26 | 1995-12-12 | The Research Foundation Of State University Of New York | Anti-tumor compounds, pharmaceutical compositions, methods for preparation thereof and for treatment |
SE9301422D0 (sv) | 1993-04-28 | 1993-04-28 | Kabi Pharmacia Ab | Method and means for inhibiting posterior capsule opacification |
US5409690A (en) | 1993-06-23 | 1995-04-25 | Chemex Pharmaceuticals, Inc. | Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol |
US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
NZ511762A (en) | 1993-07-19 | 2003-09-26 | Univ British Columbia | Anti-angiogenic compositions and methods of use |
EP1118325B2 (en) | 1993-07-29 | 2010-01-06 | The United States of America, represented by the Secretary, Department of Health and Human Services | Use of Paclitaxel and its derivatives in the manufacture of a medicament for treating restenosis. |
FR2712288B1 (fr) | 1993-11-08 | 1996-01-05 | Rhone Poulenc Rorer Sa | Nouveaux taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent. |
FR2712289B1 (fr) | 1993-11-08 | 1996-01-05 | Rhone Poulenc Rorer Sa | Nouveaux dérivés de taxicine, leur préparation et les compositions pharmaceutiques qui les contiennent. |
CA2176934A1 (en) | 1993-11-17 | 1995-05-26 | Ramnath Sasisekharan | Method for inhibiting angiogenesis using heparinase |
DE69431071T2 (de) | 1993-12-29 | 2003-03-20 | Matrix Pharma | Zusammensetzung für lokale freigabe von zytostatika |
US5565478A (en) | 1994-03-14 | 1996-10-15 | The United States Of America As Represented By The Department Of Health & Human Services | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs |
US5696153A (en) | 1994-05-16 | 1997-12-09 | Napro Biotherapeutics, Inc. | Therapeutic regimen for treating patients |
US5540934A (en) * | 1994-06-22 | 1996-07-30 | Touitou; Elka | Compositions for applying active substances to or through the skin |
US5626862A (en) | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
US5587459A (en) | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
US5583153A (en) | 1994-10-06 | 1996-12-10 | Regents Of The University Of California | Use of taxol in the treatment of rheumatoid arthritis |
US5480901A (en) * | 1994-10-07 | 1996-01-02 | Zynaxis, Inc. | Method for reducing unwanted cellular adhesions |
US5614515A (en) * | 1994-11-17 | 1997-03-25 | University Of Southern California | Lazaroid-based compositions and method for preventing adhesion formation using the same |
CA2163837C (en) | 1994-12-13 | 1999-07-20 | Robert K. Perrone | Crystalline paclitaxel hydrates |
US5654337A (en) | 1995-03-24 | 1997-08-05 | II William Scott Snyder | Topical formulation for local delivery of a pharmaceutically active agent |
US5612052A (en) * | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
US5627206A (en) | 1995-06-02 | 1997-05-06 | Warner-Lambert Company | Tricyclic inhibitor of matrix metalloproteinases |
TW354293B (en) | 1995-06-06 | 1999-03-11 | Bristol Myers Squibb Co | Prodrugs of paclitaxel derivatives |
CA2178541C (en) | 1995-06-07 | 2009-11-24 | Neal E. Fearnot | Implantable medical device |
CA2250295C (en) | 1996-03-12 | 2008-12-30 | Pg-Txl Company L.P. | Water soluble paclitaxel prodrugs |
US5635531A (en) | 1996-07-08 | 1997-06-03 | Bristol-Myers Squibb Company | 3'-aminocarbonyloxy paclitaxels |
US5773464A (en) * | 1996-09-30 | 1998-06-30 | Bristol-Myers Squibb Company | C-10 epoxy taxanes |
US6040306A (en) | 1997-11-18 | 2000-03-21 | Pharmacia & Upjohn Company | Method of treating psoriasis, arthritis and reducing the toxicity of cancer chemotherapy |
US5916913A (en) | 1998-08-03 | 1999-06-29 | Joseph; Hazel L. | Inhibition of wound contraction with paclitaxel, colchicine and penicillamine |
-
1997
- 1997-12-01 US US08/980,549 patent/US6515016B2/en not_active Expired - Fee Related
- 1997-12-02 KR KR1019997004880A patent/KR100809304B1/ko not_active IP Right Cessation
- 1997-12-02 EP EP00123557A patent/EP1070502B1/en not_active Expired - Lifetime
- 1997-12-02 BR BR9713673-5A patent/BR9713673A/pt not_active Application Discontinuation
- 1997-12-02 NZ NZ538260A patent/NZ538260A/en not_active IP Right Cessation
- 1997-12-02 AT AT05011601T patent/ATE457170T1/de not_active IP Right Cessation
- 1997-12-02 AT AT00123557T patent/ATE241977T1/de not_active IP Right Cessation
- 1997-12-02 AT AT97945697T patent/ATE201138T1/de not_active IP Right Cessation
- 1997-12-02 DE DE69739761T patent/DE69739761D1/de not_active Expired - Lifetime
- 1997-12-02 NZ NZ512097A patent/NZ512097A/en unknown
- 1997-12-02 PT PT97945697T patent/PT941089E/pt unknown
- 1997-12-02 NZ NZ336094A patent/NZ336094A/en unknown
- 1997-12-02 ES ES97945697T patent/ES2157601T3/es not_active Expired - Lifetime
- 1997-12-02 JP JP52499798A patent/JP3287852B2/ja not_active Expired - Fee Related
- 1997-12-02 WO PCT/CA1997/000910 patent/WO1998024427A2/en active IP Right Grant
- 1997-12-02 KR KR1020057018245A patent/KR20050098031A/ko not_active Application Discontinuation
- 1997-12-02 AR ARP970105661A patent/AR013878A1/es not_active Application Discontinuation
- 1997-12-02 DE DE69704877T patent/DE69704877T2/de not_active Expired - Fee Related
- 1997-12-02 CN CN200610099927.0A patent/CN101011576B/zh not_active Expired - Fee Related
- 1997-12-02 DK DK97945697T patent/DK0941089T3/da active
- 1997-12-02 EP EP00123534A patent/EP1092433B1/en not_active Expired - Lifetime
- 1997-12-02 EP EP05011601A patent/EP1582210B1/en not_active Expired - Lifetime
- 1997-12-02 DE DE69722681T patent/DE69722681T2/de not_active Expired - Lifetime
- 1997-12-02 ES ES00123534T patent/ES2207451T3/es not_active Expired - Lifetime
- 1997-12-02 CA CA002273240A patent/CA2273240C/en not_active Expired - Fee Related
- 1997-12-02 TW TW086118104A patent/TW562674B/zh not_active IP Right Cessation
- 1997-12-02 AU AU51132/98A patent/AU735655B2/en not_active Ceased
- 1997-12-02 CN CNA2006100998954A patent/CN101195028A/zh active Pending
- 1997-12-02 AT AT00123534T patent/ATE246500T1/de not_active IP Right Cessation
- 1997-12-02 CN CNA2005100547705A patent/CN1679937A/zh active Pending
- 1997-12-02 DE DE69724016T patent/DE69724016T2/de not_active Expired - Lifetime
- 1997-12-02 NZ NZ547206A patent/NZ547206A/en not_active IP Right Cessation
- 1997-12-02 CA CA002607067A patent/CA2607067A1/en not_active Abandoned
- 1997-12-02 RU RU99114020/14A patent/RU2242974C2/ru not_active IP Right Cessation
- 1997-12-02 EP EP00123537A patent/EP1090637A3/en not_active Withdrawn
- 1997-12-02 CN CNB97181581XA patent/CN1200706C/zh not_active Expired - Fee Related
- 1997-12-02 NZ NZ552215A patent/NZ552215A/en not_active IP Right Cessation
- 1997-12-02 EP EP97945697A patent/EP0941089B1/en not_active Expired - Lifetime
-
1999
- 1999-06-01 NO NO19992641A patent/NO322610B1/no not_active IP Right Cessation
-
2000
- 2000-02-28 HK HK00101207A patent/HK1022270A1/xx not_active IP Right Cessation
-
2001
- 2001-06-12 HK HK01104005A patent/HK1033422A1/xx not_active IP Right Cessation
- 2001-08-10 GR GR20010401220T patent/GR3036364T3/el not_active IP Right Cessation
- 2001-10-18 HK HK01107305A patent/HK1037320A1/xx not_active IP Right Cessation
- 2001-12-28 JP JP2001401899A patent/JP2002226399A/ja not_active Withdrawn
-
2004
- 2004-09-03 RU RU2004126705/14A patent/RU2004126705A/ru unknown
-
2006
- 2006-08-15 NO NO20063667A patent/NO20063667L/no not_active Application Discontinuation
-
2009
- 2009-03-10 JP JP2009057154A patent/JP2009161555A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2157601T3 (es) | Uso de agentes anti-microtubulos para tratar o prevenir la esclerosis multiple. | |
ES2183937T3 (es) | Inhibidores de la adhesion celular. | |
ES2186015T3 (es) | Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol. | |
PT1315504E (pt) | 1-alfa-hidroxi-2-metileno-19-nor-homopregnacalciferol e suas aplicacoes terapeuticas | |
AR021738A1 (es) | Uso de neurotoxinas para preparar composiciones para aliviar el dolor, de administracion intraespinal | |
ES2191152T3 (es) | Terapia combinada para el tratamiento de psicosis. | |
GB9807639D0 (en) | Anti-inflammatory agents | |
ES2166783T3 (es) | Factor viii activado utilizado como agente terapeutico y metodo para el tratamiento de la deficiencia de factor viii. | |
ES2178048T3 (es) | Uso de rifaximina como medicamento para el tratamiento de diarrea por criptosporidiosis. | |
UY29796A1 (es) | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
GR1002807B (el) | Συστημα για την τοπικη θεραπεια της ακμης και μεθοδος παραγωγης του | |
UY28213A1 (es) | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. | |
ES2185050T3 (es) | Utilizacion de la octoxiglicerina en una composicion cosmetica y/o dermatologica como agente activo para el tratamiento de la seborrea y/o del acne. | |
BRPI0411319A (pt) | compostos terapeuticamente ativos e sua utilização | |
ATE245452T1 (de) | Hyaluronatlyase als penetrationsförderer in topischen mitteln | |
BR9803756A (pt) | Polimento da unha antipsoriático. | |
ES2059320T3 (es) | Nuevos diarilalcanoides que tienen actividad como inhibidores de lipoxigenasa. | |
PA8457001A1 (es) | Derivados del 2-(4-aril o heteroaril-piperazin-i-ilmetil)-1h-indol | |
ES2188995T3 (es) | Uso de un inhibidor de la h+, k+-atpasa en el tratamiento de los polipos nasales. | |
ES2170798T3 (es) | Benzopiranos y su uso como agentes terapeuticos. | |
ES2137044T3 (es) | Utilizacion de derivados de oxazolidinona como agentes antipenetrantes en una composicion cosmetica y/o dermatologica. | |
ES2174337T3 (es) | Uso topico de los agonistas opioides kappa para el tratamiento del dolor ocular. | |
BR0010983A (pt) | Preparações para a aplicação de agentes antiinflamatórios | |
MXPA05010416A (es) | Combinacion de substancias activas de aceites minerales que contienen acidos grasos (3 con extractos vegetales que contengan polifenoles y su uso. | |
BG101126A (en) | The use of muramylpeptide compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 941089 Country of ref document: ES |